Politics · India Bureau
Supreme Court pushes Centre to accelerate life-saving drug price regulation
The Supreme Court has urged the government to move with greater urgency on regulating prices of life-saving drugs and medical devices. The Centre announced that anti-cancer medications will see price cuts of up to 70 percent following a decision to cap trade margins at 30 percent of maximum retail price.
LSN India ·
The Supreme Court on Monday directed the Centre to prioritize regulatory action on pricing for life-saving pharmaceuticals and devices, signalling judicial concern over delays in implementing cost-control measures.
The government responded to the court's directive by announcing a significant price reduction for anti-cancer drugs. Under the new framework, trade margins on these critical medications have been capped at 30 percent of the maximum retail price, expected to bring down costs by as much as 70 percent for patients.
The move addresses longstanding concerns about the accessibility and affordability of essential medications in India. Anti-cancer treatments have historically represented a substantial financial burden for patients and their families, often determining whether individuals can afford necessary therapy.
The court's intervention underscores the judiciary's role in ensuring that price regulation mechanisms keep pace with public health needs. The government's announcement suggests a shift toward more aggressive pricing controls on essential pharmaceutical categories, though implementation timelines remain to be clarified.
The Supreme Court's push for expedited action indicates ongoing oversight of the regulatory process, reflecting broader efforts to balance pharmaceutical industry interests with patient access to life-saving treatments across India.